SPARK THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2014 STOCK INCENTIVE PLANIncentive Stock Option Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
SPARK THERAPEUTICS INC. NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER 2014 STOCK INCENTIVE PLANNonstatutory Stock Option Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
LICENSE AGREEMENT between AAVENUE THERAPEUTICS and THE CHILDREN’S HOSPITAL OF PHILADELPHIA®License Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (the “Agreement”) is entered into this 14th day of October, 2013 (the “Effective Date”), by and between AAVenue Therapeutics, LLC, a limited liability company organized and existing under the laws of Delaware and having a principal place of business at 34th and Civic Center Blvd, Philadelphia, PA 19104 (“Company”), and The Children’s Hospital of Philadelphia®, a non-profit entity organized and existing under the laws of Pennsylvania and having a principal place of business at 34th and Civic Center Boulevard, Philadelphia, PA 19104 (“CHOP”). Each of Company and CHOP may be referred to as a “Party” and both Company and Licensor may be collectively referred to as the “Parties”.
LICENSE AGREEMENT between GENABLE TECHNOLOGIES LIMITED and SPARK THERAPEUTICS, LLCLicense Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”) is entered into this 18th day of March, 2014 (the “Effective Date”), by and between Genable Technologies Limited, organized and existing under the laws of Ireland, and having a principal place of business at Media House, South County Business Park, Leopardstown, Dublin 18, Ireland (“Genable”) and Spark Therapeutics, LLC, organized and existing under the laws of Delaware, USA, and having a principal place of business at 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA (“Spark”).
MASTER RESEARCH SERVICES AGREEMENTMaster Research Services Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Master Research Services Agreement (this “Agreement”) is made this 14th day of October, 2013 (the “Effective Date”) by and between The Children’s Hospital of Philadelphia, with a principal address at 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania (“CHOP”), and AAVenue Therapeutics, LLC, a Delaware limited liability company with a principal address at 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania (“AAVT”). CHOP and AAVT may each be referred to herein as a “Party” and together as the “Parties”.
SERVICES AGREEMENTServices Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS SERVICES AGREEMENT is entered into this 26th day of December, 2013, by and between The Children’s Hospital of Philadelphia, a Pennsylvania nonprofit corporation (“Provider”) and Spark Therapeutics, LLC, (“Recipient”) a Delaware limited liability company and is effective as of March 14, 2013 (“Effective Date”).
MANUFACTURING AGREEMENTManufacturing Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Manufacturing Agreement (this “Agreement”) is made this 18th day of March, 2014 (the “Effective Date”) by and between Spark Therapeutics, LLC, a Delaware limited liability company with a principal address at 3501 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA (“Spark”), and Genable Technologies Limited, a limited liability company with a principal address at c/o Delta Partners, Media House, South County Business Park, Leopardstown, Dublin 18, Ireland (“Genable”). Spark and Genable may each be referred to herein as a “Party” and together as the “Parties”.
TECHNOLOGY ASSIGNMENT AGREEMENTTechnology Assignment Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Technology Assignment Agreement (this “Agreement”) is entered into this 14th day of October, 2013 (“Effective Date”) by and between The Children’s Hospital of Philadelphia® (“CHOP”) and AAVenue Therapeutics, LLC, a Delaware limited liability company (the “Company”). Capitalized terms used but not otherwise defined herein shall have the meaning assigned to such terms in the Amended and Restated Limited Liability Company Agreement of the Company, dated as of October 14, 2013, as amended from time to time.
LEASE by and between WEXFORD-UCSC 3737, LLC, a Delaware limited liability company and SPARK THERAPEUTICS, LLC, a Delaware limited liability companyLease • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS LEASE (this “Lease”) is entered into as of this 31st day of March, 2014 (the “Execution Date”), by and between WEXFORD-UCSC 3737, LLC, a Delaware limited liability company (“Landlord”), and SPARK THERAPEUTICS, LLC, a Delaware limited liability company (“Tenant”).
DEVELOPMENT CONSULTANCY AGREEMENT between GENABLE TECHNOLOGIES LIMITED and SPARK THERAPEUTICS, LLCSpark Therapeutics, LLC • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Development Consultancy Agreement (the “Agreement”) is entered into this 18th day of March, 2014 (the “Effective Date”), by and between Genable Technologies Limited, organized and existing under the laws of Ireland, and having a principal place of business at Media House, South County Business Park, Leopardstown, Dublin 18, Ireland (“Genable”) and Spark Therapeutics, LLC, organized and existing under the laws of Delaware, USA, and having a principal place of business at 34th Street and Civic Center Boulevard, 5th Floor, Philadelphia, PA 19104, USA (“Spark”).
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 23rd day of May, 2014, by and among Spark Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
CONSULTING AGREEMENTConsulting Agreement • September 24th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS CONSULTING AGREEMENT (the “Agreement”), effective as of the 16 day of December, 2013 (the “Effective Date”) is entered into by Spark Therapeutics, LLC, a Delaware limited liability company (the “Company”), and Kathy A. High, M.D., an individual residing at 201 Greenway Lane, Merion Station, PA, 19066 (the “Consultant”).
